Apalutamide with Pemigatinib Interaction Details
Brand Names Associated with Apalutamide
- Apalutamide
- Erleada®
Brand Names Associated with Pemigatinib
- Pemazyre®
- Pemigatinib
Medical Content Editor Dr. Brian Staiger, PharmD
Last updated
Mar 04, 2024
Interaction Effect
Decreased pemigatinib exposure and risk of reduced efficacy
Interaction Summary
Concomitant use of pemigatinib (a CYP3A substrate) and a moderate or strong CYP3A inducer decreases pemigatinib exposure, which may reduce pemigatinib efficacy. When pemigatinib was coadministered with rifampin (a strong CYP3A inducer), the pemigatinib Cmax was decreased by 62% and AUC by 85%. Concomitant use with a moderate CYP3A inducer is predicted to decrease pemigatinib exposure by more than 50%. Concomitant use should be avoided[1].
Severity
Major
Onset
Unspecified
Evidence
Theoretical
How To Manage Interaction
Concomitant use of pemigatinib (a CYP3A substrate) and a moderate or strong CYP3A inducer decreases pemigatinib exposure, which may reduce pemigatinib efficacy and therefore should be avoided[1].
Mechanism Of Interaction
Induction of CYP3A-mediated pemigatinib metabolism
Literature Reports
A) Concomitant use of pemigatinib and rifampin, a strong CYP3A inducer, decreased pemigatinib Cmax by 62% and AUC by 85% following a single oral dose of pemigatinib 13.5 mg [1].
B) Concomitant use of pemigatinib and a moderate CYP3A inducer is predicted to decrease pemigatinib exposure by more than 50% [1].
References
1 ) Product Information: PEMAZYRE(TM) oral tablets, pemigatinib oral tablets. Incyte Corporation (per FDA), Wilmington, DE, 2020.
Apalutamide Overview
-
Apalutamide is used to treat certain types of prostate cancer (cancer in men that begins in the prostate [a male reproductive gland]) and has spread to other parts of the body or that has not spread to other parts of the body but has not been helped by other medical treatments. Apalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of cancer cells.
Pemigatinib Overview
-
Pemigatinib is used in adults who have already received a previous treatment to treat a certain type of cholangiocarcinoma (bile duct cancer) that has spread to nearby tissues or other parts of the body and cannot be removed by surgery. Pemigatinib is also used in adults to treat a certain type of myeloid/lymphoid neoplasms (MLN; a type of blood cancer) that has not improved or has come back after other treatment. Pemigatinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells.
Return To Our Drug Interaction Homepage
Feedback, Question Or Comment About This Information?
Ask Dr. Brian Staiger, PharmD, our medical editor, directly! He's always more than happy to assist.
Definitions
Severity Categories
Contraindicated
These drugs, generally, should not be used together simultaneously due to the high risk of severe adverse effects. Combining these medications can lead to dangerous health outcomes and should be strictly avoided unless otherwise instructed by your provider.
Major
This interaction could result in very serious and potentially life-threatening consequences. If you are taking this drug combination, it is very important to be under close medical supervision to minimize severe side effects and ensure your safety. It may be necessary to change a medication or dosage to prevent harm.
Moderate
This interaction has the potential to worsen your medical condition or alter the effectiveness of your treatment. It's important that you are monitored closely and you potentially may need to make adjustments in your treatment plan or drug dosage to maintain optimal health.
Minor
While this interaction is unlikely to cause significant problems, it could intensify side effects or reduce the effectiveness of one or both medications. Monitoring for changes in symptoms and your condition is recommended, and adjustments may be made if needed to manage any increased or more pronounced side effects.
Onset
Rapid: Onset of drug interaction typically occurs within 24 hours of co-administration.
Delayed: Onset of drug interaction typically occurs more than 24 hours after co-administration.
Evidence
Level of documentation of the interaction.
Established: The interaction is documented and substantiated in peer-reviewed medical literature.
Theoretical: This interaction is not fully supported by current medical evidence or well-documented sources, but it is based on known drug mechanisms, drug effects, and other relevant information.
How To Manage The Interaction
Provides a detailed discussion on how patients and clinicians can approach the identified drug interaction as well as offers guidance on what to expect and strategies to potentially mitigate the effects of the interaction. This may include recommendations on adjusting medication dosages, altering the timing of drug administration, or closely monitoring for specific symptoms.
It's important to note that all medical situations are unique, and management approaches should be tailored to individual circumstances. Patients should always consult their healthcare provider for personalized advice and guidance on managing drug interactions effectively.
Mechanism Of Interaction
The theorized or clinically determined reason (i.e., mechanism) why the drug-drug interaction occurs.
Disclaimer: The information provided on this page is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional regarding your specific circumstances and medical conditions.
Where Does Our Information Come From?
Information for our drug interactions is compiled from several drug compendia, including:
The prescribing information for each drug, as published on DailyMED, is also used.
Individual drug-drug interaction detail pages contain references specific to that interaction. You can click on the reference number within brackets '[]' to see what reference was utilized.
The information posted is fact-checked by HelloPharmacist clinicians and reviewed quarterly.